FDA Approves Rasonque (Daraxonrasib) for Metastatic Pancreatic Cancer: What Patients Need to Know
The U.S. Food and Drug Administration (FDA) has approved Rasonque (daraxonrasib), a new oral targeted cancer medicine for adults with metastatic pancreatic adenocarcinoma (PDAC). The approval marks an important development in pancreatic cancer treatment because Rasonque is designed to target RAS signaling, a major driver of pancreatic cancer.
According to Revolution Medicines, the company developing Rasonque, the medicine is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy or who are not candidates for multiagent systemic therapy.
Unlike traditional chemotherapy, Rasonque is an oral targeted therapy designed to inhibit RAS proteins in their active, cancer-driving state. The FDA approval is supported by results from the global Phase 3 RASolute 302 clinical trial, which compared Rasonque with investigator-selected chemotherapy in patients with previously treated metastatic pancreatic cancer.
What Is Rasonque?
Rasonque, also known by its generic name daraxonrasib, is a once-daily oral medicine developed by Revolution Medicines. It belongs to a new class of RAS-targeted medicines known as RAS(ON) inhibitors.
RAS proteins play an important role in controlling cell growth and signaling. When RAS signaling becomes abnormal, it can contribute to uncontrolled cancer growth. Pancreatic adenocarcinoma is particularly associated with abnormal RAS signaling, making RAS an important target for researchers developing new pancreatic cancer treatments.
Rasonque is designed to inhibit interactions between active RAS proteins and downstream signaling proteins. The goal is to reduce the signals that encourage cancer cells to grow and survive.
One notable aspect of the FDA-approved indication is that treatment does not require a companion diagnostic test to identify a specific RAS mutation. The approved population includes patients with metastatic pancreatic adenocarcinoma regardless of whether an identifiable tumor RAS mutation has been found.
FDA Approval Based on Phase 3 Trial Results
The FDA's decision was supported by results from the RASolute 302 Phase 3 trial, a randomized international study involving patients with previously treated metastatic pancreatic adenocarcinoma.
Patients received either once-daily Rasonque or one of several chemotherapy regimens selected by investigators.
The trial demonstrated substantial differences in overall survival and progression-free survival.
Among patients in the study's overall intent-to-treat population, Rasonque reduced the risk of death by approximately 60% compared with chemotherapy. The reported hazard ratio for overall survival was 0.40, with a median overall survival of 13.2 months for Rasonque compared with 6.7 months for chemotherapy.
Rasonque also improved progression-free survival. The median progression-free survival was 7.2 months with Rasonque versus 3.6 months with chemotherapy, corresponding to a hazard ratio of 0.49.
These findings suggest that targeting RAS signaling may provide a meaningful treatment option for patients whose pancreatic cancer has progressed after previous systemic treatment.
Potential Quality-of-Life Benefits
Survival is an important measure in advanced cancer treatment, but quality of life is also a major consideration for people living with metastatic pancreatic cancer.
The RASolute 302 trial included patient-reported assessments of health status, quality of life and pain.
Patients receiving Rasonque experienced a longer time before deterioration in global health status and quality of life. The median time to deterioration was 5.7 months with Rasonque compared with 2.6 months with chemotherapy.
The treatment also delayed worsening of clinically significant pain. The median time to deterioration in pain was 9.2 months for Rasonque compared with 3.8 months for chemotherapy.
These findings are particularly relevant because metastatic pancreatic cancer can cause substantial symptoms and can significantly affect daily activities and overall well-being.
Rasonque Availability in the United States
Rasonque is approved as a 300 mg once-daily oral tablet and is available by prescription in the United States, according to Revolution Medicines.
The company has also launched a patient support program called (ON)Path, which is intended to assist eligible patients with areas such as insurance navigation, financial assistance and treatment education.
Patients considering Rasonque should discuss access, insurance coverage, potential financial assistance and treatment costs with their healthcare team and the appropriate patient-support resources.
Common Side Effects and Safety Information
Although Rasonque offers a new targeted approach, it can cause significant side effects and requires medical monitoring.
The most frequently reported adverse reactions, occurring in at least 20% of patients in the relevant clinical studies, included:
- Rash
- Diarrhea
- Stomatitis and other oral problems
- Nausea
- Fatigue
- Vomiting
- Abdominal pain
- Edema
- Decreased appetite
- Hemorrhage
The prescribing information also includes important warnings and precautions involving dermatologic and soft tissue toxicity, stomatitis, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity.
For example, dermatologic toxicity occurred frequently in clinical trials. The prescribing information reports dermatologic toxicity in 86% of patients with pancreatic adenocarcinoma treated with Rasonque, including Grade 3 events in 10%.
Stomatitis occurred in 57% of patients, while diarrhea occurred in 63%. Gastrointestinal perforation and interstitial lung disease or pneumonitis were less common but potentially serious complications.
Rasonque can also interact with other medicines. Certain CYP3A and P-glycoprotein inhibitors or inducers may require avoidance, dosage adjustments or changes in how medications are taken.
Because of these risks, Rasonque should only be taken according to a healthcare professional's prescription and instructions.
Why the Approval Matters for Pancreatic Cancer
Pancreatic adenocarcinoma remains one of the most difficult cancers to treat. The disease is often diagnosed after it has already spread, limiting treatment options.
The FDA approval of Rasonque introduces a targeted oral therapy into a treatment setting where chemotherapy has historically played a central role.
The significance of the approval also extends beyond pancreatic cancer. Rasonque is being investigated as a potential treatment for other RAS-driven cancers, including certain forms of non-small cell lung cancer and colorectal cancer.
However, approval status differs by country and cancer type. In the United States, Rasonque is currently approved for the specific metastatic pancreatic cancer population described in the FDA indication. Other uses may remain investigational.
What Patients Should Ask Their Doctors
Patients with metastatic pancreatic cancer may want to discuss several questions with their oncologist before starting treatment.
These can include whether they meet the FDA-approved indication, how Rasonque compares with other available treatment options, what side effects to expect, which medications may interact with Rasonque, and what monitoring will be required.
Patients should also ask about strategies for preventing or managing skin reactions, mouth problems and diarrhea, as well as when symptoms require urgent medical attention.
The appropriate treatment depends on an individual's cancer characteristics, previous treatments, overall health, medications and personal preferences.
Looking Ahead
The FDA approval of Rasonque represents a significant development in efforts to directly target RAS-driven cancer. Results from RASolute 302 showed improvements in overall survival, progression-free survival and several patient-reported outcomes compared with chemotherapy in the studied population.
Further research will determine how Rasonque fits into broader pancreatic cancer treatment strategies and whether its potential can be demonstrated in other RAS-driven cancers.
For people living with metastatic pancreatic adenocarcinoma, the approval provides another treatment option and adds to ongoing progress in a disease where new therapeutic approaches remain urgently needed.
Source
- Revolution Medicines, Inc. Rasonque (daraxonrasib) Prescribing Information, August 2026.
- Revolution Medicines, Inc., announcement regarding the FDA approval of Rasonque and results from the RASolute 302 Phase 3 clinical trial, August 26, 2026.
Medical Disclaimer
This article is not intended to provide medical advice, diagnosis or treatment recommendations. Rasonque (daraxonrasib) is a prescription medicine and may cause serious or potentially life-threatening side effects. Patients should speak with a qualified healthcare professional before starting, stopping or changing any cancer treatment. Always consult the FDA-approved prescribing information and your healthcare provider for the most current information about indications, contraindications, warnings, drug interactions, side effects and appropriate use.